Lilly to Present Phase 3 EMBER-3 Study Results for Imlunestrant at San Antonio Breast Cancer Symposium
Eli Lilly and Company (NYSE: LLY) has announced that data from the Phase 3 EMBER-3 trial of imlunestrant, an oral selective estrogen receptor degrader (SERD), will be presented for the…
Ma Xin, Jiangsu Vice Governor, Visits Hansoh Pharma Subsidiary
On the morning of October 30, Ma Xin, a member of the Standing Committee of the Jiangsu Provincial Party Committee and Executive Vice Governor, visited Jiangsu Hansoh, a subsidiary of…
ASN 2024 | Hansoh Pharma Shares Post-Hoc Results from Phase III Pegmolesatide Study
The 2024 American Society of Nephrology (ASN) Kidney Week conference took place at the San Diego Convention Center from October 23 to 27. During this event, a post-hoc analysis of…
Teva Unveils New Schizophrenia Research: Positive Phase 3 TEV-‘749 and UZEDY® Data
Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has announced encouraging new data from the Phase 3 SOLARIS trial on TEV-‘749, a subcutaneous extended-release…
Teva Presents New TD Data at Psych Congress 2024, Highlighting Patient Differences
Teva Pharmaceuticals, the U.S. branch of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has released interim findings from its Phase 4 IMPACT-TD Registry study. This large-scale study sheds light…
New WHO Report Highlights Urban Efforts in Preventing NCDs and Injuries
On World Cities Day, the World Health Organization (WHO) launched a new report highlighting how urban areas can tackle the increasing challenges posed by noncommunicable diseases (NCDs) and injuries. As…
Uganda and WHO Launch Strategies to Enhance Healthcare for Refugees and Migrants
A new report titled “Refugee and Migrant Health System Review: Challenges and Opportunities for Long-Term Health System Strengthening in Uganda” was launched on October 15 by Uganda’s Ministry of Health…
Updated Consolidated Financial Forecasts and Introduction of Core-Based Financial Reporting
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Toichi Takino; “the Company”) today announced that it has revised its consolidated financial forecasts for the full-year period ending March 2025 disclosed at…
Halozyme Announces Q3 2024 Financial and Operational Results
Halozyme Therapeutics, Inc. (NASDAQ: HALO) released its third-quarter 2024 financial and operational results, showcasing strong revenue growth and notable corporate developments. CEO Commentary on Performance and Growth “Our third-quarter performance…
Blueprint Medicines Q3 2024 Results & Increased Full-Year Revenue Guidance for AYVAKIT®/AYVAKYT®
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced its financial results and business highlights for the third quarter ended September 30, 2024, along with updated financial guidance. Strong AYVAKIT Performance and…
Bachem’s Sustainable Approach to TIDES Manufacturing
The pharmaceutical industry is evolving toward sustainability, with increasing awareness of the need for eco-friendly practices. Therapeutic peptides and oligonucleotides (TIDES) present particular challenges due to their traditionally resource-heavy manufacturing…
18-Year-Old Pyry Shadows SVP of R&D for a Day: I Aspire to Make a Social Impact
Exciting, Challenging, and Insightful – This Is the Impression Pyry Simi, an 18-year-old from Tampere, Gained of the Pharmaceutical Industry After Spending a Day with Outi Vaarala, SVP of Innovative…